% | $
Quotes you view appear here for quick access.

AcelRx Pharmaceuticals, Inc. Message Board

  • titusmabon titusmabon Nov 14, 2012 4:54 PM Flag

    When Expect News

    When do we expect any further news from this company and what do you expect the price to move to? I am a shareholder but am thinking of a significant increase in shares. Opinions are welcomed.

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • According to JMP Securities:

      In-line Q3 results with key value inflecting catalysts fast approaching; reiterate Market
      Outperform rating and $8 price target for AcelRx Pharmaceuticals. AcelRx reported 3Q12
      earnings roughly in-line with our and consensus estimates and ended the quarter with cash of
      approximately $23MM, which we view as sufficient to fund operations through 2Q13. Progress is
      continuing with the ARX-01 Phase III development program and top-line results from the first of
      three Phase III trials are expected to be announced later this month. We continue to believe that
      the company’s innovative sufentanil-based platform addresses key unmet needs for post-surgical
      pain patients and can offer clinical and pharmaeconomic advantages over current post-operative
      IV PCA.

      Sentiment: Buy

2.95-0.05(-1.67%)4:00 PMEDT